The multi-million Swiss franc amount will enable the clinical implementation of FastSkin® treatment, a revolutionary method for treating chronic and acute wounds. The proceeds are planned to drive the launch of the first wound care product in the US market in the second half of 2024. The financing round was led by Heraeus Group and was supported by Asia Jetway Pte, a Singapore-based holding company that produces and distributes health solutions in Asia through its subsidiaries LandMover, Shanghai Keyman, Lader, Healthy Medical and Jiangsu Lekaibio. The investment will rapidly advance the development and commercialisation of FastSkin®. This revolutionary treatment has the potential to significantly improve the quality of care for patients and reduce healthcare costs.
About Heraeus
The Heraeus Group is a broadly diversified and globally leading family-owned technology company, headquartered in Hanau, Germany. The company’s roots go back to a family pharmacy started in 1660. Today, Heraeus bundles diverse activities in the Business Platforms Metals and Recycling, Healthcare, Semiconductor and Electronics as well as Industrials. Customers benefit from innovative technologies and solutions based on broad materials expertise and technological leadership. In the 2022 financial year, the group generated revenues of €29.1 billion (US$30.6 billion*) with approximately 17,200 employees in 40 countries. Heraeus is one of the top 10 family-owned companies in Germany and holds a leading position in its global markets.
(* calculated with 2022 average exchange rate, 1€ = 1.0530 US$)
About Mimix Biotherapeutics Ltd.
Established in 2019, the company leverages Sound Induced Morphogenesis (SIM), a proprietary technology that uses sound in conjunction with cells, stem cells, spheroids, organoids & bioactives, to create tissue-relevant architectures (bio-patterns). SIM replicates nature’s design strategy by controlling shape & function, the two fundamentals in developmental biology.
Sound-induced morphogenesis is born of over a decade of intensive research and development incubated at the AO Foundation in Davos, Switzerland.
Headquartered in the Swiss Innovation Park in Biel/Bienne, MimiX is focusing its energies on clinical translation, with its first product, FastSkin®. FastSkin®, an advanced dermal substitute designed to treat acute and chronic wounds, uses the cutting-edge biofabrication technique of soundinduced morphogenesis (SIM).
MimiX Biotherapeutics is seeking FDA approval for FastSkin®, which is set to revolutionize the industry as the world's first clinical acoustic cell patterning product. This milestone marks a turning point in regenerative medicine and underscores MimiX's commitment to improving the future of healthcare.
For more information visit www.mimixbio.com.
